Jan 29, 2002|
Ranbaxy: Sales on target, margins disappoint
Ranbaxy has declared a 26% rise in sales and 4% rise in net profit for the last quarter of FY02. While sales growth has been more or less in line with our expectations, the growth in operating margin for the fourth quarter has disappointed. Bouyed by a huge rise in export income, we were expecting operating margins in the range of 17%-18%. Consequently, the net profit for the year fell short of our estimates by Rs 160 m.
|Operating Profit (EBDIT)
|Operating Profit Margin (%)
|Profit before Tax
|Profit after Tax/(Loss)
|Net profit margin (%)
|No. of Shares (eoy) (m)
|Diluted Earnings per share*
|P/E (at current price)
For the full year, while domestic pharma division has grown by around 9%, more or less in line with market expectations, exports have registered a growth of 28% during the year. Last quarter has seen exports growing at a faster clip on the back of generic launch of Ibuprofen (combination) and Lorazepam in September’01. The Ibuprofen combination was the first successful Para IV approval from Ranbaxy’s stable. Also, Lorazepam is an anti-anxiety drug with market size close to US$ 400 m.
The year was marked with considerable presence of one time (extra-ordinary) charges and income in the company's financials. In the first quarter of FY01, Ranbaxy received Rs 233 m (US $ 5 m) as technology licensing income from Bayer AG. Again in the third quarter, there was an extra-ordinary income of Rs 727 m on account of profit from sale of its stake in joint venture with Eli Lilly. The company booked Rs 300 m loss on account of its stock market activity through its subsidiary, Vidyut Investments. Other income which primarily consisted of interest income fell considerably during the year due to discontinuance of its stock market operations.
The company has ramped up its product approvals in last few months for the International markets. The latest one being, generic manufacturing and marketing approval for all combinations of Lisinopril drug, which is a multi-billion cardiovascular molecule. The company currently has a basket of 44 products for the US markets, far ahead of any other Indian generic company. The company's strategy of targeted penetration in Germany, Brazil and UK also seems to be working well.
Read more on Export strategy of the company.
On a standalone basis, Ranbaxy has already achieved revenues in excess of US$ 440 m. The US subsidiaries of the company have recorded revenues to the tune of US$ 113 m, a growth of 74%. The company closed the year with a consolidated revenues of US$ 596 m. The international operations of the company which was hitherto in red has logged in profit before tax of close to US$ 7m. The company has already achieved critical mass in the International pharma scene. At the current market price of Rs 744, the stock is trading at a P/e of 36x FY02 earnings (on a standalone basis). Success in generics business and positive surprises on R&D front are likely to be key stock price triggers for the company going forward.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
TRACK RANBAXY LAB
- Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks